According to the FDA 2026 approvals listing, the agency listed Tauklarify (florquinitau F 18) on August 13, 2026, for tau PET brain imaging, a tracer injection and scan that reveals tau tangles. For adults with mild cognitive impairment evaluated for Alzheimer disease, it offers a new approved way to check for that tau pathology.
Mild cognitive impairment means memory or thinking changes that are noticeable but do not block daily life. Many conditions can cause it, so doctors test for Alzheimer-related brain changes. Tau imaging adds a tau-specific measure to that workup.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official notice from FDA — Use this primary source to verify the official announcement.
- Read the official notice from Psychiatrictimes — Use this primary source to verify the official announcement.
Table of Contents
- What does the scan show?
- Who is it meant for?
- How consistent were reads and how safe was it?
- What are the key limits?
- How does it fit with amyloid and blood tests?
What does the scan show?
Tauklarify was previously called MK-6240. Psychiatric Times, reporting the approval, says it binds selectively to clumped tau protein and makes neurofibrillary tangles visible on PET after injection.
A positive result signals that tau tangle pathology was detected in the scanned regions. A doctor interprets that pattern alongside symptoms, memory testing, and other Alzheimer evaluations.
Who is it meant for?
The approval covers adults with cognitive impairment who are being evaluated for Alzheimer disease. Psychiatric Times reports the trials enrolled people with mild cognitive impairment and mild Alzheimer disease, plus unimpaired controls for comparison. That history matters for readers now: Ask the ordering clinician whether your symptoms and evaluation fit that labeled use.
- adults with cognitive impairment evaluated for Alzheimer disease are the labeled group
- people with mild cognitive impairment were represented in the supporting trials
- people with mild Alzheimer disease were also represented in the trials
How consistent were reads and how safe was it?
Efficacy rested on blinded reads in phase 3 studies with more than 500 patients across three trials. According to Psychiatric Times reporting on the Lantheus announcement, positive reader agreement was 80%-88% in study 1 and 68%-82% in study 2, and safety review in more than 1,700 subjects found mostly headache at 0.7% and nausea at 0.2%.
Rare events included injection-site reactions, dizziness, and abdominal discomfort at 0.1% each. The tracer involves radiation exposure and an intravenous injection, so the clinic explains precautions before the visit. Tell staff about prior contrast or tracer reactions, pregnancy, breastfeeding, and kidney or liver issues.
What are the key limits?
A negative scan does not necessarily rule out tau pathology. Enigma Biomedical USA notes that safety and effectiveness are not established for non-Alzheimer tau diseases, as described by HealthTech HotSpot coverage of the approval.
That means the result is Alzheimer-evaluation information, not a standalone diagnosis or a test for other tau disorders. Timing also matters because tau burden can change as disease progresses. Keep follow-up appointments even after a result.
How does it fit with amyloid and blood tests?
Tau imaging complements amyloid PET and blood tests by helping clarify stage and progression. According to Being Patient reporting on the approval, that staging role can help patients and families understand where symptoms sit in the Alzheimer continuum.
The same reporting notes head-to-head data suggesting MK-6240 may detect tangles earlier than Tauvid. Earlier visibility does not by itself change treatment, but it can sharpen discussions about monitoring, trial eligibility, and care planning.
You Might Also Like
- How 2026 Tau Imaging News May Affect Alzheimer’s Workups: Questions People With Mild Cognitive Impairment Can Bring to a Clinician
- Tauklarify Tau PET vs Alzheimer’s Blood Tests in 2026: Questions People With Mild Cognitive Impairment Can Bring to a Clinician
- Day-One Subcutaneous Leqembi for Early Alzheimer’s in 2026: Questions People With Mild Cognitive Impairment Can Ask an Alzheimer’s Specialist
